Research and Markets: Anxiety Disorders - Pipeline Review, H2 2012

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/l53r37/anxiety_disorders) has announced the addition of Global Markets Direct's new report "Anxiety Disorders - Pipeline Review, H2 2012" to their offering.

“Anxiety Disorders - Pipeline Review, H2 2012”

This report provides information on the therapeutic development for Anxiety Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anxiety Disorders.

Anxiety Disorders - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- A snapshot of the global therapeutic scenario for Anxiety Disorders.

- A review of the Anxiety Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Anxiety Disorders pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Companies Involved in Anxiety Disorders Therapeutics Development

- Johnson & Johnson

- Avineuro Pharmaceuticals, Inc.

- AcelRx Pharmaceuticals, Inc.

- Eisai Co., Ltd.

- Addex Pharmaceuticals

- Neuralstem, Inc.

- Ligand Pharmaceuticals Incorporated

- NovaDel Pharma, Inc.

- Ironwood Pharmaceuticals, Inc.

- Abiogen Pharma S.p.A.

- Global Health Ventures Inc.

- Psylin Neurosciences, Inc.

- Azevan Pharmaceuticals, Inc.

- CeNeRx BioPharma, Inc.

- Concert Pharmaceuticals, Inc.

- Omeros Corporation

- Targacept, Inc.

- Vanda Pharmaceuticals Inc.

- Adamed Sp. z o.o.

- NeuroTherapeutics Pharma Inc.

- Cannasat Therapeutics, Inc.

- Lee's Pharmaceutical Holdings Limited

- Heptares Therapeutics Ltd.

- Pherin Pharmaceuticals, Inc.

- Beech Tree Labs, Inc.

- Naurex, Inc.

For more information visit http://www.researchandmarkets.com/research/l53r37/anxiety_disorders

Source: Global Markets Direct